Truist Financial Corp reduced its holdings in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) by 7.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,727 shares of the company’s stock after selling 376 shares during the quarter. Truist Financial Corp owned about 0.23% of iShares U.S. Pharmaceuticals ETF worth $847,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Private Capital Management LLC acquired a new position in iShares U.S. Pharmaceuticals ETF during the fourth quarter worth $205,000. Blair William & Co. IL acquired a new position in iShares U.S. Pharmaceuticals ETF during the first quarter worth $58,000. First Manhattan Co. acquired a new position in iShares U.S. Pharmaceuticals ETF during the first quarter worth $46,000. Transcend Capital Advisors LLC acquired a new position in iShares U.S. Pharmaceuticals ETF during the second quarter worth $201,000. Finally, Commonwealth Equity Services LLC raised its holdings in iShares U.S. Pharmaceuticals ETF by 2.1% during the first quarter. Commonwealth Equity Services LLC now owns 13,615 shares of the company’s stock worth $2,386,000 after purchasing an additional 283 shares during the last quarter.
iShares U.S. Pharmaceuticals ETF Stock Performance
Shares of IHE stock opened at $174.16 on Wednesday. The stock has a fifty day moving average price of $179.84 and a 200 day moving average price of $179.97. The stock has a market cap of $357.03 million, a PE ratio of 18.82 and a beta of 0.70. iShares U.S. Pharmaceuticals ETF has a 1 year low of $166.09 and a 1 year high of $191.74.
iShares U.S. Pharmaceuticals ETF Profile
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Featured Stories
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Utilities Stocks Explained – How and Why to Invest in Utilities
- GSK is a remedy for the winter investment blahs
- Most Volatile Stocks, What Investors Need to Know
- After blowout earnings, Integer may be headed to new highs
- What is a Low P/E Ratio and What Does it Tell Investors?
- Banking and trucking: Is the economy rolling toward troubles?
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
